Russell Trenary , President and Chief Executive Officer of Outlook Therapeutics , to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15 letters In NORSE TWO, ONS-5010 was safe and well tolerated Management to host conference call and webcast

Experienced executive with a track-record of successful eye care product launches Appointment reflects Outlook Therapeutics’ dedication to transition to commercial-stage company ISELIN, N.J. , July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

ISELIN, N.J. , June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that as part of the annual

Topline readout of data from NORSE TWO targeted for calendar Q3 2021 New Biologics License Application (BLA) filing anticipated in calendar Q1 2022 ISELIN, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to

Drs. Mark Humayun and Firas Rahhal , leading retinal specialists and Advisors to Outlook Therapeutics , stress clinical value of ONS-5010, if approved, over existing treatment options Registration clinical program and pre-commercialization planning for ONS-5010 remains ongoing with key catalysts

Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021 Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience trial (NORSE ONE) ISELIN,

Live video webcast with Outlook Therapeutics’ management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ET ISELIN, N.J. , May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the

Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on

MONMOUTH JUNCTION, N.J. , March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence